Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2017

View Archived Issues

Aptevo Therapeutics to sell hyperimmune commercial products to Saol Therapeutics

Fresenius Kabi closes acquisition of Merck KGaA's biosimilars business

Takeda and Noile-Immune Biotech enter a collaboration to advance next generation CAR-T cell therapy

GlaxoSmithKline, ViiV identify new HIV allosteric integrase inhibitors

ReViral begins dosing in phase IIa study of RV-521 for RSV

Promising RORgammaT inhibitors discovered at Merck & Co.

FDA places clinical hold on phase I studies of UCART-123

Increased SIRT4 expression linked to accelerated heart failure development

Novartis reports promising data from phase III study of fingolimod in pediatric MS

Enrollment completed in phase IIb study of BGS-649 for hypogonadotropic hypogonadism

PMV Pharmaceuticals describes novel compounds restoring mutant p53 function

Concert Pharmaceuticals presents new PPARalpha, PPARdelta agonists

Vanderbilt University divulges novel muscarinic acetylcholine M1 receptor modulators

Novel bile acid receptor agonists discovered at Alios BioPharma

Golden Biotechnology presents new compounds for liver cancer

First-in-human phase I results for (Z)-endoxifen in endocrine-refractory metastatic breast cancer

Axxam and Sanofi begin neurodegeneration research collaboration

Funding pledged to Global Antibiotic Research and Development Partnership

New phase I/II study investigates H3B-6545 in advanced ER-positive, HER2-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...